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Genetic techniques have recently implicated two
different ion channels as critical molecular targets
for the sedative action of ethanol and intravenous
anesthetics. In each case, the target is hyperacti-
vated by the drug. 
A wide variety of drugs alter neural function. For many
such agents — such as opiates, muscle relaxants and
local anesthetics — the way they produce their effect is
known. In these cases, pharmacologists have not only
identified a receptor that binds the drug, but have also
shown that altered receptor function accounts for the
drug effect. The benefits of knowing a drug target are
enormous: it enables screening for improved drugs, the
analysis of drug interactions and the study of drug resis-
tance. In contrast to these pharmacological success
stories, targets have remained elusive for many of the
drugs that induce hypnosis, sedation, or anesthesia. In
large measure, this reflects the tendency of sedating
drugs to bind weakly and broadly to cellular compo-
nents. This makes it hard to trap a unique complex and
hard to focus on a single drug-induced change. For
these difficult cases, it has been long appreciated that
a genetic approach could usefully complement bio-
chemical and physiological analysis.
The basic idea is that genetic variation in a
significant drug target should be associated with an
altered drug response. Although the implementation of
this idea would seem straightforward, success has
been a long time in coming. Multiplicity of drug
targets, redundancy in target gene families, and com-
pensatory gene expression have all undoubtedly con-
tributed to the delay. A further obstacle has been the
difficulty in distinguishing mutations that affect the
target from those that alter a bypass pathway. But in
the past year there have at last been two exemplary
cases in which the genetic approach has demon-
strated its power. In both cases the implicated target
is an ion channel — a γ-amino-butyric acid (GABA)-
gated chloride channel for the sedative effects of
intravenous anesthetics [1] and a calcium-activated
potassium channel for the locomotor effects of
ethanol [2] — and in both cases the drugs produce
their effects by increasing channel function.
Propofol and etomidate are two commonly used
intravenous general anesthetics that have similar phar-
macology. Prominent amongst the many actions pro-
duced by clinical concentrations of these drugs
(1–5 µM) is the ability to increase chloride currents
flowing through GABA-gated channels, an action that
depresses neuronal excitability [3]. If this action were
responsible for the sedative and hypnotic effects of
these drugs, deletion of the gene encoding the target
channel should render an organism insensitive to them.
Accordingly, knockout mice bearing targeted disrup-
tions of genes encoding subunits of GABA-gated chlo-
ride channels have been evaluated for sensitivity to
propofol and/or etomidate.
The results of these studies were disappointingly
modest, but this might only have been because some
knockouts were too sick to test well and others were
masked by compensatory expression of another
channel [4,5]. If so, a more effective test of the putative
propofol/etomidate target could be fashioned using a
variant channel that is specifically defective in the
binding and/or action of the drugs but works well in
their absence. Happily, such mutants are known [6]: the
lab of Uwe Rudolph [7] engineered one of these muta-
tions (N265M) into a particular subunit (β3) and showed
it had the desired effect on GABA channels expressed
in heterologous cells. They then created a ‘knock-in’
mouse in which the indigenous copy of the β3 gene
was replaced by the drug-insensitive version [1].
The result of this experiment was all one could ask
for. In contrast to the very sickly β3 knockout mice [8],
the β3 knock-in mice were found to be healthy, but to
have a much reduced sensitivity to propofol and
etomidate [1]. Most dramatically, the mutant mice con-
tinued to display a normal motor response to a noci-
ceptive stimulus despite the injection of either drug at
levels more than sufficient to obliterate this reflex in
wild-type mice. This single experiment provides the first
definitive proof that, as long suspected, the GABA
channel is the critical target for these intravenous anes-
thetics in mice and thus presumably in man. It further
shows that, of the many different versions of this
channel, those containing the β3 subunit are the most
important for drug action.
Dwarfing the study of intravenous anesthetics in both
urgency and difficulty is the problem of identifying the
targets by which ethanol influences the nervous system.
The urgency comes from the huge personal and societal
cost arising from use of this drug. The difficulty stems
from the multiple changes caused by inebriating con-
centrations of ethanol (>5 mM), making it very hard to
sort out pertinent from incidental effects. Consequently,
there has been a long and serious investment in genetic
studies of alcohol effects in laboratory animals. This has
involved both breeding/selection schemes to identify
quantitative trait loci (QTL) [9] and, more recently,
directed manipulation of candidate genes [10]. 
These studies have shown that many single genes
can influence the alcohol response in whole animals,
but they have not determined if any of these encode
direct targets of ethanol as opposed to influencing the
way the nervous system accommodates drug-induced
changes. Standing out against this background is a
recent study [2] in which genetic and physiological
assays were combined to identify a potassium channel
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as the major ethanol target in the nervous system of the
nematode Caenorhabditis elegans.
Davies et al. [2] focused on drug effects on two motor
programs: locomotion and egg laying. They mutage-
nized wild-type worms and looked for mutants with
altered sensitivity to the depressive actions of ethanol.
After screening ~20,000 individuals, a single gene stood
out as affecting both endpoints: slo-1, which encodes
one of the nematode members of the BK or slowpoke
family of ion channels [11]. These are voltage- and
calcium-activated potassium channels which provide
negative feedback to calcium signalling (Figure 1). All
the new mutants were resistant to the effects of ethanol,
and the responsible mutations appeared to reduce or
eliminate gene function. The implication is that, if the
slo-1 gene product really is a target of ethanol, the drug
should augment BK currents. 
Previous work had shown this is indeed the case for
some of the vertebrate members of the BK family [12],
and Davies et al. [2] confirmed it for SLO-1. Importantly,
drug effects are seen even with patches of membrane
ripped from the cell, so ethanol appears to alter BK
function directly, rather than through action on modu-
lators. That ethanol acitvation of the nematode BK
channel is not just necessary but sufficient to produce
locomotor defects is implied by the phenotype of gain-
of-function mutations that increase channel function.
Worms with these mutations [13] have depressed rates
of locomotion and egg-laying [2], as if they were already
inebriated despite the absence of exogenous ethanol. 
How general is the ethanol–BK channel connection?
In higher organisms, ethanol acutely influences not just
locomotory performance but also short-term memory
and pain sensation. Equally important are the tolerance
and dependence that accompany chronic ingestion of
ethanol. Does hyperactivation of SLO-1 produce any of
these effects in C. elegans? And to what extent does
this channel account for the effects of ethanol in higher
organisms? This question most obviously applies to the
acute changes in locomotor performance induced by
alcohol. But, as the nematode hyperactive slo-1 mutants
show altered gene expression during neural develop-
ment [13], the question may also be applied to a possi-
ble role for SLO-1 in the developmental anomalies
associated with prenatal alcohol exposure [14].
One must be cautious, however, about extrapolating
from C. elegans to Homo sapiens. In nematodes, as
judged from a screen for suppressors of a syntaxin
mutant [15], there appears to be a very strong func-
tional connection between SLO-1 and the synaptic
release machinery. If such a strong connection is pecu-
liar to C. elegans, BK homologs may be a less promi-
nent drug target in other organisms. Nevertheless, the
success of the screen for ethanol resistance stands as
a landmark for the power of the genetic approach to
single out biologically relevant targets for low-affinity,
low-specificity drugs.
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Figure 1. A nematode synaptic terminal, showing the
presumptive relationship between the BK channel and
neurotransmitter release.
When axonal depolarization reaches the terminal, voltage-gated
Ca2+ channels (brown) are activated, and Ca2+ (blue arrow)
enters. In response to elevated Ca2+, synaptic vesicles (red) fuse
with the presynaptic membrane, releasing neurotransmitter. The
combination of depolarization and elevated Ca2+ also activates
BK channels (green), resulting in efflux of K+. This helps to repo-
larize the terminal, closing Ca2+ channels and limiting neuro-
transmitter release. The ethanol-mediated increase in BK
channel activity thus shortens the period of activity and reduces
synaptic transmission, ultimately causing depressed locomotion
and egg-laying.
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